mhb039a
mAbexperimentalBi-specific
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2024 (NCT06345482)
Timeline
Indications
Mechanism of action
- Programmed cell death protein 1INHIBITOR
PDCD1 inhibitor
- Vascular endothelial growth factor AINHIBITOR
VEGFA inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07130383 | Phase 2 | Sep 30, 2025 | Minghui Pharmaceutical Pty Ltd |
| NCT07126665 | Phase 1/Phase 2 (Phase 2) | Sep 18, 2025 | Minghui Pharmaceutical Pty Ltd |
| NCT07229599 | Phase 1/Phase 2 (Phase 2) | May 9, 2025 | Minghui Pharmaceutical Pty Ltd |
| NCT06345482 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2024 | Jiao Tong University, Minghui Pharmaceutical Pty Ltd |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Minghui Pharmaceutical Pty Ltd | For profit | 4 | 4 | 1 | 2024 |
| Jiao Tong University | Academic/Hospital | 1 | 0 | 1 | 2024 |
2 organizations
Page 1 / 1